CNS Pharmaceuticals, Inc. (CNSP) stock
Close on Nov 12, 2026Market cap $5.29MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $5.29M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.29
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$16.70M
- EPS, diluted
- -$23.14
- Free cash flow
- -$13.83M
- Book value per share
- $2.66
- Diluted shares
- 7M
Trading
- Previous close
- $3.62
- Open
- $3.70
- Day's range
- $3.62 – $3.70
- Volume
- 2,863
- Average volume (20 days)
- 17,750
- Beta (5 years)
- 1.67
- 52-week range
- $1.90 – $10.54
- RSI (14 days)
- 31.4
- Volatility (1 year)
- 253.6%
- Relative volume
- 0.32×
- WACC
- 13.2%
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CNSP | S&P 500 | Difference | CNSP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -30.3% | -2.7% | −27.6 pts | ||
| 3 months | -27.7% | -1.7% | −26.0 pts | ||
| Year to date | -31.0% | +11.9% | −42.9 pts | ||
| 1 year | -45.1% | +12.0% | −57.1 pts | ||
| 3 years | -100.0% | +78.2% | −178.2 pts | -95.6% | +21.2% |
| 5 years | -100.0% | +73.2% | −173.2 pts | -92.0% | +11.6% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases CNS Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- Update
- Update
- News
About CNS Pharmaceuticals
Pharmaceutical Preparations
CNS Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies for serious neurological conditions and cancers. The company seeks to build a portfolio of differentiated preclinical and clinical-stage drug candidates by identifying, acquiring, or in-licensing assets that offer defined biological rationales and clear regulatory pathways. Historically centered on advancing treatments for glioblastoma multiforme, including investigational compounds such as TPI 287 and Berubicin designed to cross the blood-brain barrier, the company has pivoted toward broader opportunities across neurology and oncology. Its primary target populations comprise patients diagnosed with severe neurodegenerative disorders and various oncological malignancies.
Company profile, executives and historyCNS Pharmaceuticals stock: common questions
What is CNS Pharmaceuticals's stock price?
CNSP closed at $3.62 on Nov 12, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $1.90 and $10.54.
What is CNS Pharmaceuticals's market cap?
CNS Pharmaceuticals was worth $5.29M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is CNSP's P/E ratio?
CNS Pharmaceuticals lost money over the twelve months to Jun 30, 2026 (diluted EPS -$23.14), so it has no meaningful P/E ratio.
Does CNS Pharmaceuticals pay a dividend?
No. CNS Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has CNSP stock performed over the past year?
Including dividends, CNSP returned -45.1% over the past year, against +12.0% for the S&P 500.
How many CNSP shares are sold short?
0M shares were sold short at the latest FINRA report, 0.15% of the float, or 1.0 days of average trading volume.
Who are CNS Pharmaceuticals's competitors?
Companies most similar to CNS Pharmaceuticals by business, industry and size include NERV, CRVO, PRAX, IGC, NTHI.
See a number that looks wrong?